UA111959C2 - Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом - Google Patents

Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом

Info

Publication number
UA111959C2
UA111959C2 UAA201308448A UAA201308448A UA111959C2 UA 111959 C2 UA111959 C2 UA 111959C2 UA A201308448 A UAA201308448 A UA A201308448A UA A201308448 A UAA201308448 A UA A201308448A UA 111959 C2 UA111959 C2 UA 111959C2
Authority
UA
Ukraine
Prior art keywords
improving
multiple sclerosis
laquinimod
functional status
life
Prior art date
Application number
UAA201308448A
Other languages
English (en)
Ukrainian (uk)
Inventor
Нора Таркік
Дан Бар-Зохар
Діна Кофлер
Original Assignee
Тева Фармасьютікл Індастріз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA111959(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Фармасьютікл Індастріз Лтд. filed Critical Тева Фармасьютікл Індастріз Лтд.
Publication of UA111959C2 publication Critical patent/UA111959C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201308448A 2010-12-07 2011-12-06 Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом UA111959C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04
PCT/US2011/063460 WO2012078591A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Publications (1)

Publication Number Publication Date
UA111959C2 true UA111959C2 (uk) 2016-07-11

Family

ID=46162796

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201308448A UA111959C2 (uk) 2010-12-07 2011-12-06 Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом

Country Status (19)

Country Link
US (1) US20120142730A1 (https=)
EP (1) EP2648732A4 (https=)
JP (2) JP2013544887A (https=)
KR (1) KR20130124518A (https=)
CN (1) CN103260624B (https=)
AU (2) AU2011338647A1 (https=)
BR (1) BR112013014061A2 (https=)
CA (1) CA2820586A1 (https=)
CL (1) CL2013001602A1 (https=)
EA (1) EA201390827A1 (https=)
IL (1) IL250726A0 (https=)
MX (1) MX2013006464A (https=)
NZ (1) NZ611628A (https=)
PE (1) PE20140872A1 (https=)
PH (1) PH12013501193A1 (https=)
SG (2) SG10201509831XA (https=)
UA (1) UA111959C2 (https=)
WO (1) WO2012078591A1 (https=)
ZA (1) ZA201304237B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567088A (en) * 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015003608A (es) * 2012-09-27 2015-06-05 Teva Pharma Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
BR112015007782A2 (pt) * 2012-10-12 2017-07-04 Teva Pharma laquinimod para reduzir danos talâmicos na esclerose múltipla
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
BR112015019564A2 (pt) * 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US20160038435A1 (en) 2013-03-14 2016-02-11 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
CA2933380A1 (en) * 2013-12-20 2015-06-25 Esther Lukasiewicz Hagai Use of laquinimod to delay huntington's disease progression
HK1225969A1 (zh) * 2014-01-17 2017-09-22 Teva Pharmaceutical Industries Ltd 利用低剂量的拉喹莫德治疗克隆氏病
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN114699409A (zh) * 2014-10-16 2022-07-05 诺华股份有限公司 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
WO2020076809A1 (en) * 2018-10-09 2020-04-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
BR112022001138A2 (pt) * 2019-07-22 2022-03-15 Actelion Pharmaceuticals Ltd Métodos de tratamento de esclerose múltipla
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
EP2680010A1 (en) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
JP2012530701A (ja) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療

Also Published As

Publication number Publication date
EP2648732A4 (en) 2014-04-30
EA201390827A1 (ru) 2013-12-30
WO2012078591A1 (en) 2012-06-14
CN103260624A (zh) 2013-08-21
ZA201304237B (en) 2014-08-27
SG10201509831XA (en) 2015-12-30
CN103260624B (zh) 2015-06-03
NZ611628A (en) 2015-06-26
AU2011338647A8 (en) 2013-09-05
EP2648732A1 (en) 2013-10-16
KR20130124518A (ko) 2013-11-14
PH12013501193A1 (en) 2013-07-15
BR112013014061A2 (pt) 2016-09-13
WO2012078591A8 (en) 2012-08-02
MX2013006464A (es) 2013-07-29
SG190449A1 (en) 2013-07-31
IL250726A0 (en) 2017-04-30
JP2013544887A (ja) 2013-12-19
CL2013001602A1 (es) 2013-10-25
AU2017202055A1 (en) 2017-04-20
JP2017095476A (ja) 2017-06-01
US20120142730A1 (en) 2012-06-07
CA2820586A1 (en) 2012-06-14
AU2011338647A1 (en) 2013-07-04
PE20140872A1 (es) 2014-08-09

Similar Documents

Publication Publication Date Title
UA111959C2 (uk) Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
NZ601167A (en) Treatment of cardiac conditions
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
MX2014001557A (es) Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
EA033415B1 (ru) Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
MY199027A (en) Method for treating or preventing ophthalmological conditions
EP2811832A4 (en) USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MORBUS CROHN AFTER FAILED PREVIOUS ANTI-TNF THERAPY
NZ602478A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
SG11201400301XA (en) An orthopedic chair for treatment and prevention of spinal diseases
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
IL260078B (en) Therapy used to treat Gaucher disease
PH12014500381A1 (en) Therapeutic methods
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
GB201318377D0 (en) Drug-free compositions and methods for diminishing peripheral inflammation and pain
CY1119845T1 (el) Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος
ZA201306759B (en) Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system
HK1188950A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
NZ726034A (en) Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine